State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine; Key Laboratory for Biomedical Engineering of Ministry of Education, Zhejiang University, Hangzhou, 310003, Zhejiang, China; Department of Biomedical Engineering, Key Laboratory of Biomedical Engineering of Ministry of Education of China, Zhejiang Provincial Key Laboratory of Cardio-Cerebral Vascular Detection Technology and Medicinal Effectiveness Appraisal, Zhejiang University, Hangzhou, 310027, Zhejiang, China.
Institute of Analytical Chemistry, Department of Chemistry, Key Laboratory of Excited-State Materials of Zhejiang Province, Zhejiang University, Hangzhou, 310058, Zhejiang, China.
Talanta. 2023 Sep 1;262:124626. doi: 10.1016/j.talanta.2023.124626. Epub 2023 May 6.
Heart-type fatty acid binding protein (H-FABP) is an early biomarker for acute myocardial infarction. The concentration of H-FABP in circulation sharply increases during myocardial injury. Therefore, fast and accurate detection of H-FABP is of vital significance. In this study, we developed an electrochemiluminescence device integrated with microfluidic chip (designed as m-ECL device) for on-site detection of H-FABP. The m-ECL device is consisted of a microfluidic chip that enable easy liquid handling as well as an integrated electronic system for voltage supply and photon detection. A sandwich-type ECL immunoassay strategy was employed for H-FABP detection by using Ru (bpy) loaded mesoporous silica nanoparticles as ECL probes. This device can directly detect H-FABP in human serum without any pre-treatment, with a wide linear range of 1-100 ng/mL and a low limit of detection of 0.72 ng/mL. The clinical usability of this device was evaluated using clinical serum samples from patients. The results obtained from m-ECL device are well matched with those obtained from ELISA assays. We believe this m-ECL device has extensive application prospects for point-of-care testing of acute myocardial infarction.
心脏型脂肪酸结合蛋白（H-FABP）是急性心肌梗死的早期生物标志物。H-FABP 在循环中的浓度在心梗损伤期间急剧增加。因此，快速准确地检测 H-FABP 具有重要意义。在本研究中，我们开发了一种与微流控芯片集成的电化学发光装置（设计为 m-ECL 装置），用于现场检测 H-FABP。m-ECL 装置由一个微流控芯片组成，该芯片便于进行液体处理，以及一个集成的电子系统，用于提供电压和检测光子。采用三明治型 ECL 免疫分析策略，使用负载 Ru（bpy）的介孔硅纳米粒子作为 ECL 探针检测 H-FABP。该装置可直接检测人血清中的 H-FABP，无需任何预处理，线性范围为 1-100ng/mL，检测限低至 0.72ng/mL。使用来自患者的临床血清样本评估了该装置的临床可用性。m-ECL 装置获得的结果与 ELISA 测定法获得的结果非常匹配。我们相信，这种 m-ECL 装置在急性心肌梗死的即时护理检测方面具有广泛的应用前景。
